U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H17N5O8S2
Molecular Weight 435.433
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SQ-28429

SMILES

C[C@H]1[C@H](NC(=O)C(=N\OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O

InChI

InChIKey=WZPBZJONDBGPKJ-IYZXUIDESA-N
InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8+/t5-,7-/m0/s1

HIDE SMILES / InChI

Molecular Formula C13H17N5O8S2
Molecular Weight 435.433
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/27334663

Aztreonam is the first monocyclic beta-lactam antibiotic (monobactam) originally isolated from Chromobacterium violaceum. Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria. Most of these organisms are inhibited and killed at low concentrations of the drug. Aztreonam must be administered as an intravenous or intramuscular injection (AZACTAM®), or inhaled (CAYSTON®). Aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract, lower respiratory tract, skin and skin-structure, intra-abdominal and gynecologic infections as well as for septicemia. Aztreonam for inhalation solution is indicated to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

Originator

Sources: ISBN-13: 978-1461413998

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.03 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Curative
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

5.363712E11
Palliative
CAYSTON

Approved Use

CAYSTON® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Launch Date

1.26679686E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
204 μg/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
54 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
90 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
208 mg × h/L
1 g 1 times / day steady-state, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
AZTREONAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.67 h
1 g 1 times / day steady-state, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
AZTREONAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
44%
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg/kg single, intravenous
Recommended
Dose: 30 mg/kg
Route: intravenous
Route: single
Dose: 30 mg/kg
Sources:
unhealthy, 10 - 18 years
n = 10
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 10 - 18 years
Sex: unknown
Population Size: 10
Sources:
1 g single, intramuscular
Recommended
Dose: 1 g
Route: intramuscular
Route: single
Dose: 1 g
Sources:
unhealthy, 18 - 75 years
n = 102
Health Status: unhealthy
Condition: urogenital gonorrhoea
Age Group: 18 - 75 years
Sex: M+F
Population Size: 102
Sources:
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Other AEs: Pain, Erythema...
Other AEs:
Pain (12%)
Erythema (2.9%)
Induration (0.9%)
Phlebitis (2.1%)
Blood eosinophils increased (6.3%)
Increased platelets (3.6%)
Neutropenia (3.2%)
AST increased (3.8%)
ALT increased (6.5%)
Increased serum creatinine (5.8%)
Sources:
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 612
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 612
Sources:
Other AEs: Rash, Diarrhea...
Other AEs:
Rash (4.3%)
Diarrhea (1.4%)
Fever (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Induration 0.9%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Pain 12%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Phlebitis 2.1%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Erythema 2.9%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Neutropenia 3.2%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Increased platelets 3.6%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
AST increased 3.8%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Increased serum creatinine 5.8%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Blood eosinophils increased 6.3%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
ALT increased 6.5%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 343
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 343
Sources:
Fever 1%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 612
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 612
Sources:
Diarrhea 1.4%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 612
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 612
Sources:
Rash 4.3%
1 g 3 times / day steady, intramuscular (median)
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
unhealthy, children
n = 612
Health Status: unhealthy
Condition: infections
Age Group: children
Sex: unknown
Population Size: 612
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome.
1987 Oct
In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria.
1988 Dec
Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
1998 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050814s007lbl.pdf
Urinary tract infections (adults): 0.5-1 g 2-3 times/day. Moderately severe systemic infections (adults): 1-2 g 2-3 times/day. Severe systemic or life-threatening infections (adults): 2 g 3-4 times/day. Maximum recommended dose for adults is 8 g per day. Mild to moderate infections (pediatric patients): 30 mg/kg 3 times/day Moderate to severe infections (pediatric patients): 30 mg/kg 3-4 times/day. Maximum recommended dose for pediatric patients is 120 mg/kg/day. Inhalation solution: one dose (one single use vial and one ampule of diluent) 3 times a day for 28 days.
Route of Administration: Other
In Vitro Use Guide
In vitro, minimum inhibition concentration (MIC) values against almost all of the Enterobacteriaceae, Neisseria and Haemophilus strains were below 1 microgram per milliliter. MIC values against Pseudomonas aeruginosa were about 8 ug/ml.
Substance Class Chemical
Created
by admin
on Thu Jul 06 10:46:50 UTC 2023
Edited
by admin
on Thu Jul 06 10:46:50 UTC 2023
Record UNII
5Q55M3D9UA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SQ-28429
Common Name English
AZTREONAM E-ISOMER
Common Name English
PROPANOIC ACID, 2-(((1-(2-AMINO-4-THIAZOLYL)-2-((2-METHYL-4-OXO-1-SULFO-3-AZETIDINYL)AMINO)-2-OXOETHYLIDENE)AMINO)OXY)-2-METHYL-, (2S-(2.ALPHA.,3.BETA.(E)))-
Common Name English
(E)-2-((((2-AMINO-4-THIAZOLYL)(((2S,3S)-2-METHYL-4-OXO-1-SULFO-3-AZETIDINYL)CARBAMOYL(METHYLENE)AMINO(OXY)-2-METHYLPROPIONIC ACID
Common Name English
SQ 28429
Code English
AZTREONAM E-ISOMER [USP-RS]
Common Name English
PROPANOIC ACID, 2-(((E)-(1-(2-AMINO-4-THIAZOLYL)-2-(((2S,3S)-2-METHYL-4-OXO-1-SULFO-3-AZETIDINYL)AMINO)-2-OXOETHYLIDENE)AMINO)OXY)-2-METHYL-
Common Name English
Code System Code Type Description
FDA UNII
5Q55M3D9UA
Created by admin on Thu Jul 06 10:46:51 UTC 2023 , Edited by admin on Thu Jul 06 10:46:51 UTC 2023
PRIMARY
PUBCHEM
5459211
Created by admin on Thu Jul 06 10:46:51 UTC 2023 , Edited by admin on Thu Jul 06 10:46:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID20244045
Created by admin on Thu Jul 06 10:46:51 UTC 2023 , Edited by admin on Thu Jul 06 10:46:51 UTC 2023
PRIMARY
RS_ITEM_NUM
1046307
Created by admin on Thu Jul 06 10:46:51 UTC 2023 , Edited by admin on Thu Jul 06 10:46:51 UTC 2023
PRIMARY
CAS
99341-02-3
Created by admin on Thu Jul 06 10:46:51 UTC 2023 , Edited by admin on Thu Jul 06 10:46:51 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP